0001209191-20-044347.txt : 20200731 0001209191-20-044347.hdr.sgml : 20200731 20200731201625 ACCESSION NUMBER: 0001209191-20-044347 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200509 FILED AS OF DATE: 20200731 DATE AS OF CHANGE: 20200731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Boissel Stephane CENTRAL INDEX KEY: 0001755198 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 201067546 MAIL ADDRESS: STREET 1: C/O SANGAMO THERAPEUTICS, INC. STREET 2: POINT RICHMOND TECH CTR, 501 CANAL BLVD. CITY: RICHMOND STATE: CA ZIP: 94804 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-09 1 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001755198 Boissel Stephane C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD BRISBANE CA 94005 0 1 0 0 EVP, Corp. Strategy Free Shares Call Options (obligation to sell to Issuer) 2020-05-09 5 E 0 E 1 0.00 D 2020-03-09 2020-05-09 Common Stock 2 D Free Shares Call Options (obligation to sell to Issuer) 2020-07-03 5 E 0 E 1 0.00 D 2020-05-03 2020-07-03 Common Stock 1 D In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning May 3, 2019 (the "Free Shares Call Options"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329. On May 9, 2020, the Free Shares Call Option with respect to the second tranche of Subject Free Shares (or 80,000 Subject Free Shares) expired unexercised. On July 3, 2020, the Free Shares Call Option with respect to the third tranche of Subject Free Shares (or 52,700 Subject Free Shares) expired unexercised. /s/ Matthew Colvin, Attorney-in-Fact for Stephane Boissel 2020-07-31